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The Absence of Donor-Derived IL-13 Exacerbates the Severity of Acute
Graft-Versus-Host Disease Following Allogeneic Bone Marrow Transplantation
Gerhard C. Hildebrandt, MD,1,2* Sung W. Choi, MD,2 Gunnar Mueller,1 Krystyna M. Olkiewicz, MS,2
Bethany B. Moore, PhD,3 and Kenneth R. Cooke, MD2
INTRODUCTION
Allogeneic (allo-) bone marrow transplantation (BMT) is the
only curative option for a number of malignant and non-malignant
diseases. The utility of allo-BMT is limited by the development of
acute graft versus host disease (aGVHD) [1]. Experimental and
clinical data suggest that aGVHD is predominantly mediated by a
Th1-type cytokine response [2,3], although an additive role for Th1
andTh2 cells has been described [4]. Interestingly, the production of
Interleukin-13 (IL-13) by donor T cells responding to host antigens
in vitro was recently shown to correlate with the severity of clinical
aGVHD [5]. IL-13 is a typical Th2-type cytokine that is produced by
a wide variety of cells including T cells [6,7]. IL-13 binds to its
functional receptor (IL-13R) that consists of the IL-4Ra chain and
the IL-13Ra1 chain [8] or to a decoy receptor, called IL-13Ra2 [9].
IL-13 exhibits a range of biologic activities, some of which overlap
with those observed with IL-4 [10–12]. Although T lymphocytes
are a significant producer of IL-13, these cells do not express the IL-
13R on their surface and therefore do not respond to this cytokine
[13]. We used a well-established murine BMT model (BALB/cB6)
and mice deficient in IL-13 as BMT donors to more clearly
determine the role of donor T cell derived IL-13 in the pathogenesis
of aGVHD.
MATERIAL AND METHODS
Mice and Bone Marrow Transplantation
Female BALB/c IL-13þ/þ (H-2d) and C57BL/6 (H-2b) mice
were purchased from Jackson Laboratories (Bar Harbor, ME).
BALB/c IL-13/ (H-2d)micewere provided byAndrewMcKenzie
[14]. Animals were housed and fed as previously described [15].
Mice received BMT as described previously [16]. C57BL/6 mice
received 13 Gy total body irradiation (TBI; 137Cs source) split into
two doses followed by intravenous injection of 5 106 bonemarrow
(BM) and 2 106 CD4þ and CD8þ magnetic-bead-purified
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) splenic
T cells from either syngeneic B6, allogeneic BALB/c IL-13þ/þ or
allogeneic BALB/c IL-13/ donors. Survival was monitored daily
until day 180.
Fluorescence-activated Cell Sorting (FACS) Analysis
Cells were analyzed by FACS using fluorescein isothiocyanate-
conjugated monoclonal antibodies to CD8 and phycoerythrin-
conjugated antibodies to CD4 (BD Pharmingen, San Diego, CA) as
described [15].
Acute graft versus host disease (aGVHD) after allogeneic bone
marrow transplantation (allo-BMT) predominantly involves a Th1-
type cytokine response. Interestingly, the Th2-cytokine, Interleukin-
13 (IL-13), produced by alloreactive donor T cells in vitro was
recently shown to correlate with clinical aGVHD severity. Using an
established mouse model, we show that the systemic cytokine milieu
following allo-BMT with IL-13/ donors is characterized by
decreases in serum Th2 cytokines and an increase in serum TNFa,
and ultimately correlates with higher aGVHDmortality compared to
allogeneic controls. In vitro studies further demonstrate that both
exogenous and T cell-derived IL-13 can regulate TNFa production
by macrophages following lipopolysaccharide stimulation. Thus,
donor-derived IL-13 may have a role in modulating inflammatory
cytokine release that is associated with aGVHD. Pediatr Blood
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T Cell Proliferation
Donor T cell expansion in the spleen was assessed in vivo 7 and
14 days following BMT as described [15]. Antigen-specific T cell
proliferation in vitro was assessed in mixed lymphocyte reactions
(MLR) [15]. C57BL/6, BALB/c IL-13þ/þ or BALB/c IL-13/ T
cells were plated at a concentration of 2 105 cells/well with
2 104 C57BL/6 splenic DCs isolated as described [15]. At 96 hr,
supernatants were collected for cytokine analysis, responder cells
were pulsed with 3[H] thymidine and proliferation was determined
24 hr later on a 1205 Betaplate reader (Packard, Downers, Grove,
IL). As a positive control, T cell proliferation in response to
Concavalin A was also determined [15]. In some experiments,
C57BL/6 peritoneal cells were pre-incubated with recombinant
IL-13 (6 hr) or MLR supernatants (4 hr) prior to stimulation with
lipopolysaccharide (LPS) to produce TNFa.
Measurement of Cytokine Protein Levels by ELISA
Concentrations of IFNg, IL-13 in serum (day þ7 after BMT)
and/or cell culture supernatants were measured in duplicate by
ELISA (IFNg: OptEIA; BD Pharmingen. IL-13: Biosource;
Camarillo, CA). Serum levels of TNFa, IL-2,-4,-5 were determined
by Cytokine Bead Array (Th1/Th2 cytokine kit, BD Pharmingen).
Assay methods and limits of detection were followed as per the
specific protocol.
Statistical Analysis
Values are expressed as the mean S.E.M. Statistical compar-
isons between groups were completed using the parametric
independent sample t-test. Survival curves were plotted using
Kaplan–Meier estimates. The log-rank test was used to analyze
survival data.
RESULTS AND DISCUSSION
We investigated the role of IL-13 produced by donor cells in the
pathogenesis of aGVHD. First, we determined whether the absence
of IL-13 in T lymphocytes alters alloantigen-specific responses
in vitro. C57BL/6, BALB/c IL-13þ/þ and BALB/c IL-13/ T cells
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Fig. 1. IL-13 production regulates mortality after allogeneic BMTand TNFa production in vivo and in vitro. Lethally irradiated C57BL/6 mice
were transplanted from either syngeneic C57BL/6 (&;—), allogeneic BALB/c IL-13þ/þ (&;- - -) or allogeneic BALB/c IL-13/ (&;. . .) donors
as described in Materials and Methods. a: Allogeneic BMT from IL-13/ donors resulted in significantly increased GVHD-related mortality
compared to animals receiving allogeneic IL-13þ/þ donor cells. Data presented are combined from four experiments; n¼ 12–31 per group; each
experiment concurrently included animals of all groups;P< 0.02.b: Compared to animals receiving allogeneic IL-13þ/þBMT, serumTNFa levels
in recipients of allogeneic IL-13/ cells were significantly elevated on day 7 (and on day 14; data not shown) after BMT. Data are presented as
mean  standard error and are combined from three experiments; n¼ 9–15 per group; P< 0.05. c: Pre-incubation of peritoneal cells with
recombinant IL-13 reduces TNFa production following LPS stimulation. Data are presented as mean  standard error. d: TNFa production of
peritoneal cells to LPS stimulation is reduced following pre-incubation with supernatant obtained fromMLRs using IL-13þ/þT cellsþ allogeneic
APCs compared to pre-incubation with conditionedmedia obtained using IL-13/ T cellsþ allogeneic APCs. In each case, TNFameasurements
were normalized to those obtained when peritoneal cells were pre-incubated with supernatants collected followingMLRs with IL-13þ/þT cells or
IL-13/ T cells þ media alone. Data are from one of two similar experiments.
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were stimulated with B6 splenic DCs. BALB/c IL-13þ/þ and
IL-13/ T cells proliferated comparably well in response to B6
alloantigens compared to syngeneic controls (Supplemental Figure
1a) and only modest changes in IFNg (P< 0.05) and IL-2 (n.s.)
production were seen in vitro but not in vivo between allogeneic
groups (Supplemental Figure 1b and c). While allogeneic wild-type
T cells produced significant amounts of IL-13 in culture, IL-13
levels in MLRs using allogeneic IL-13/ T cells were low and did
not differ from syngeneic controls (Supplemental Figure 1d).
Further, IL-5 (Supplemental Figure 1e) and IL-4 (not shown)
production by IL-13/ T cells were also significantly reduced,
indicating a general decrease in Th2 cytokine production. Consistent
with previous reports [14], similar results were obtained after non-
specific T cell stimulation with Con A (Supplemental Figure 1a–e).
We next determined the effects of IL-13 deficiency in donor
cells on splenic T cell expansion and the resultant pro-
inflammatory cytokine milieu characteristically observed follow-
ing allo-BMT. Lethally irradiated B6 mice received BMT from
either syngeneic (B6) or allogeneic (Balb/c IL-13þ/þ or Balb/c
IL-13/) donors. Compared to syngeneic controls, T cells from
allogeneic IL-13þ/þ and IL-13/ expanded significantly and
equally in the spleen following BMT (Supplemental Figure 2a).
Serum levels of IFNg, IL-2, IL-5 and IL-13 were all elevated in
mice 7 days after allo-BMT from IL-13þ/þ donors compared to
syngeneic controls. Concentrations of IL-13 and IL-5, but not
IFNg or IL-2 were significantly reduced following IL-13/ BMT
compared to levels measured in allogeneic IL-13þ/þ controls
(Supplemental Figure 2b–e). Serum IL-4 levels were not
detectable in any group.
Th2 cytokine responses have been shown to abrogate the
intensity of aGVHD in vivo [17]. We hypothesized that the
reduction in Th2 cytokine production following IL-13/ BMT
would correlate with increased aGVHD severity. As shown in
Figure 1a, 90% of recipients of allo-BMT from IL-13/ donors
died of aGVHD by day 150. By contrast, animals receiving allo-
BMT from IL-13þ/þ donors showed a significant reduction in
aGVHD mortality (P< 0.02). Mortality was associated with
increased serum TNFa levels after allo-BMT, and TNFa levels
were significantly higher after allo-BMT with IL-13/ cells
compared to recipients of allogeneic IL-13þ/þ BMT (Fig. 1b). We
hypothesized that the enhanced mortality seen following allo-
BMT with IL-13/ donors were secondary to the loss of the
immunomodulatory effects of IL-13 on macrophage function and
TNFa secretion [18]. To test this, we pre-incubated B6 peritoneal
cells prior to LPS stimulation with either recombinant IL-13, or
supernatants collected from MLRs using either IL-13þ/þ or IL-
13/ T cells. The latter design was chosen to reproduce in vitro,
aspects of immune dysregulation that were occurring in vivo
following allo-BMT. As shown in Figure 1c, the addition of
recombinant IL-13 to cell culture prior to LPS stimulation
resulted in a significant reduction in TNFa production by
peritoneal cells in a dose-dependent fashion. Similar reductions
were observed when peritoneal cells were pre-incubated with
supernatants collected from MLRs using T cells capable of
producing IL-13 (IL-13þ/þ) compared to the conditioned media
collected from T cells that could not (Fig. 1d). Collectively, these
data suggest that donor derived IL-13 down-regulates TNFa
production following allo-BMT. This effect in combination with
the ability of IL-13 to augment the secretion of Th2 cytokines
such as IL-4 or IL-5 or other immunomodulatory proteins like
TGFb [19–21] may contribute to a protective role of IL-13 in
aGVHD pathophysiology. The previously described correlation
between the in vitro production of IL-13 by donor T cells and
clinical aGVHD [5] offers an interesting approach to predict
GVHD pre-transplant. However, since alloreactive T cells are a
significant source of IL-13 (Supplemental Figure 1d), this
correlation may simply reflect the overall allo-activation status
of these cells rather that a direct link between IL-13 and GVHD
severity. While our data support this hypothesis, it is possible that
IL-13 could directly enhance target organ injury in a Th2-
mediated manner [4]. Whether proinflammatory effects of IL-13,
such as those seen with airway hyperresponsiveness, eosinophilia
and fibrosis [19,22,23], play a functional role in chronic GVHD
remains to be determined.
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Identification of A Novel p53 In-Frame Deletion in a Li–Fraumeni-Like Family
Joshua D. Schiffman, MD,1* Nicolette Chun, MS,2 Paul G. Fisher, MD,1 Gary V. Dahl, MD,1
James M. Ford, MD,2 and Faye A. Eggerding, MD, PhD3
INTRODUCTION
Li–Fraumeni syndrome (LFS) is a rare familial cancer syndrome
originally identified through analysis of rhabdomyosarcoma
patients and their families [1]. Classic LFS is characterized by
bone or soft tissue sarcoma before age 45 years in an individual with
a first degree relative diagnosed with cancer before age 45, and one
additional first or second degree relative diagnosedwith cancer at an
early age or sarcoma at any age [2–4]. Families that exhibit a
clustering of LFS cancers but do not conform to all the features of
classic LFS are labeled Li–Fraumeni-like (LFL) families. LFL
syndrome is characterized by occurrence of a LFS-related cancer
before age 45 years in an individual with two first or second degree
relative with LFS-related malignancies [5].
Germlinemutations in the p53 tumor suppressor gene located on
chromosome17p13 have been identified in 70–80%ofLFS families
and in 20–40%ofLFL families [2,4,6,7].Germline and somatic p53
mutations are similar, with the majority missense substitutions
resulting in defective transcriptional regulation. Inactivating germ-
line mutations in the p53 gene are highly penetrant and individuals
harboring p53 mutations have an elevated risk for multiple primary
cancers [8].Herewe report the identification of a novel p53 germline
mutation in a child with pilocytic astrocytoma and leukemia, in a
LFL family with a clustering of brain tumors.
CLINICAL REPORT
A previously healthy 2 1/2-year-old presented with a seizure.
BrainMRI revealed a left parietal tumor. The tumor was completely
resected and found to be a pilocytic astrocytoma (WHOgrade I). No
adjuvant therapy was necessary.
At age 4 years, she presented with pallor, hepatosplenomegaly,
and fever. Peripheral blood white cell count was 21,800/mm3 with
90% lymphoblasts. Bone marrow aspirate confirmed the diagnosis
of B-progenitor cell acute lymphoblastic leukemia (ALL). Cytoge-
netic analysis identified the TEL/AML-1 fusion gene in lympho-
blasts. Therewas no central nervous system disease. After two years
of treatment per Pediatric OncologyGroup protocols 9900 and 9904
regimen D, she is now on maintenance chemotherapy.
A family history revealed the death of the patient’s father
secondary to glioblastoma multiforme at age 46. The patient’s
paternal uncle died secondary to glioblastoma at age 48. The
patient’s mother is healthy. The maternal grandmother developed
breast cancer at age 60, and died at age 61 from heart failure. A
family pedigree is in Figure 1. A diagnosis of LFL syndrome was
considered. The mother consented to p53 genotyping for the patient
We describe a 2-year-old female with a completely resected
cerebral pilocytic astrocytoma who subsequently developed B-
progenitor acute lymphoblastic leukemia (ALL). Her father and
paternal uncle were previously diagnosed with glioblastoma multi-
forme. Sequence analysis of the patient’s p53 gene revealed a novel
germline three base-pair deletion (339_341delCTT) in exon 4,
resulting in removal of an evolutionarily conserved phenylalanine
amino acid residue at codon 113. The same mutation was found in
the patient’s two clinically unaffected siblings. The in-frame
deletion we describe has not previously been reported and adds
to our understanding of the biologic effects of p53 gene mutation
in Li–Fraumeni syndrome (LFS). Pediatr Blood Cancer 2008;50:
914–916.  2007 Wiley-Liss, Inc.
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